Stem cell transplant using half-matched donor and cyclophosphamide
Part of Blood & lymphatic clinical trials.
This trial tests a stem cell transplant option for children or young adults with severe aplastic anemia that did not respond to prior immune-suppressing treatment. It uses a “half-matched” donor and gives post-transplant cyclophosphamide to help the donor cells work and reduce certain immune reactions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 3 to 35 years old
- Your aplastic anemia is “refractory,” meaning it didn’t improve after at least one course of anti-thymocyte globulin (ATG) immune treatment
- You do NOT have an identical donor or a fully matched 10/10 donor, but you DO have a half-matched donor (haploidentical) such as a parent, sibling, adult child, or cousin
- You should not have strong antibodies against the donor’s type (donor-specific antibodies; test result MFI must be below 1500)
- Your heart, liver, and kidney tests must be good enough for high-dose cyclophosphamide (plus no severe uncontrolled infection)
- If you can become pregnant or cause pregnancy: you must use reliable birth control during the study and for several months after the last cyclophosphamide dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing whether a stem cell transplant (from a matched relative, unrelated donor, or half-matched donor) can help adults aged 40–60 with severe aplastic anemia that didn't get better or came back after standard treatments.
This trial tests a “half-matched” stem cell transplant for children and teens with severe aplastic anemia when a fully matched donor isn’t available. It may help rebuild blood-making cells after prior treatments did not work well enough.
This trial tests whether giving children with aplastic anemia a transplant using a matched unrelated donor (a bone marrow donor who is not a family member) can help treat their condition. It aims to see if this approach is effective and safe for children who qualify.
This trial tests a new way of using a mix of donor stem cells (from a half-matched family member and a cord blood unit) to treat aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal is to see if this transplant approach is safe and helps rebuild healthy blood cells.
This trial tests a rescue stem cell transplant using a half-matched donor and a drug called cyclophosphamide to help the new stem cells grow and prevent rejection. It may help people whose first transplant failed.
This Phase 1 trial tests a “lower-intensity” chemotherapy plan followed by a stem cell transplant from a related half-match donor for severe aplastic anemia that has returned or did not respond to prior medicines. It aims to see if this approach is safe and works well enough to help your blood counts recover.
Hear when a new Refractory Idiopathic Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.